Media coverage about Perrigo (NYSE:PRGO) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Perrigo earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.4225319260321 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Perrigo (PRGO) Hits 52-Week High: What’s Driving the Stock? (zacks.com)
- Perrigo Trying To Close In On Key Technical Benchmark (finance.yahoo.com)
- Elagolix May Advance the Treatment Paradigm in Women’s Health (finance.yahoo.com)
- Recent Developments for Mylan (finance.yahoo.com)
- Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07pc (newkerala.com)
Shares of Perrigo (NYSE PRGO) traded down $0.19 on Friday, hitting $91.80. 559,700 shares of the company’s stock traded hands, compared to its average volume of 1,007,144. Perrigo has a one year low of $63.68 and a one year high of $92.75. The firm has a market capitalization of $12,960.00, a PE ratio of -10.02, a price-to-earnings-growth ratio of 1.92 and a beta of 0.64. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.24 and a current ratio of 1.72.
Perrigo (NYSE:PRGO) last announced its earnings results on Thursday, November 9th. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.11 by $0.28. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company posted $1.65 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. sell-side analysts forecast that Perrigo will post 4.88 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, December 19th. Shareholders of record on Friday, December 1st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date was Thursday, November 30th. Perrigo’s payout ratio is -6.99%.
Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald set a $107.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research report on Friday. Leerink Swann assumed coverage on shares of Perrigo in a research report on Tuesday, January 2nd. They set a “market perform” rating and a $90.00 price objective for the company. Canaccord Genuity set a $100.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research report on Monday, January 1st. Argus upgraded shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a research report on Friday, December 8th. Finally, Barclays raised their price objective on shares of Perrigo to $93.00 and gave the company an “overweight” rating in a research report on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $92.00.
In related news, VP Todd W. Kingma sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the sale, the vice president now directly owns 19,565 shares in the company, valued at $1,731,893.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP John Wesolowski sold 450 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $83.09, for a total transaction of $37,390.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,051 shares of company stock valued at $355,370. Corporate insiders own 6.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://transcriptdaily.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-perrigo-prgo-share-price.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.